Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Perspective
Whither the GBMA in a biosim dominated market?
The departure of Belinda Wood from the helm of the GBMA presents an opportunity to consider what role this group can play in the future Australian medicines market.
Approvals Action
New heart pain drug registered
Menarini has registered a new heart pain drug while Sanofi continues to add to Clexane options to address its impending patent expiry.
Pipeline Monitor
Gilead scores first win from Kite buyout
Gilead has received its first FDA approval for newly acquired CAR-T Yescarta following its USD12 billion buyout of original sponsor Kite Pharma in August.